Business Context and Reporting Period
Pacific Biosciences of California, Inc. filed this Form 8-K on May 19, 2016, to report a significant corporate event regarding its capital structure.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the authorization of a new equity offering.
- Offering Size: Up to $30,000,000 aggregate offering price of common stock.
- Sales Agent: Cantor Fitzgerald & Co.
- Commission: 3.0% of the gross sales price per share sold.
- Use of Proceeds: General corporate purposes, including capital expenditures and working capital.
Material Changes
The Company announced its intention to sell shares through an "at the market offering" (Rule 415). This offering is in addition to shares previously sold under the existing Controlled Equity Offering Sales Agreement dated October 5, 2012 (as amended). The filing does not report material changes to prior period financial results.
Outlook, Risks, and Unusual Items
Management Commentary: The Company is not obligated to make any sales under the agreement. Sales will be made based on the Company's instructions regarding price, time, or size limits.
Termination Conditions: The offering will terminate upon the earlier of the sale of all shares subject to the agreement or the termination of the agreement by either Cantor or the Company.
Constraints: Sales are subject to limits ensuring they do not exceed shares registered on Form S-3, authorized but unissued shares, or shares permitted under General Instruction I.B.6 of Form S-3.
Investor Verification Checklist
- Verify the current number of authorized but unissued shares to ensure the $30 million offering does not exceed this limit.
- Review the effective Registration Statement on Form S-3 (File No. 333-199891) and the prospectus supplement dated May 19, 2016.
- Monitor future filings to track the actual volume of shares sold and the total proceeds raised under this agreement.
- Assess the impact of the 3.0% commission on the net proceeds available for capital expenditures and working capital.